Royalty Pharma plc
HealthcareNASDAQ:RPRX · NASDAQ Global Select
-$0.14 today
Vol 1.57M · Avg 3.65M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $586.4M |
| Short-term Investments | $21.9M |
| Receivables | $807.4M |
| Other Current | $10.2M |
| Total Current Assets | $1.4B |
| Goodwill | $924.6M |
| Intangible Assets | $16.5B |
| Long-term Investments | $845.8M |
| Other Non-current | $76.8M |
| Total Non-current Assets | $18.4B |
| Total Assets | $19.8B |
Analysis
Selected assets total $19.8B for Latest. The largest visible component is Intangible Assets at $16.5B, about 83.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $618.7M -33.4% | $929.0M +94.8% | $477.0M -72.1% | $1.7B +11.0% | $1.5B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $18.8M -97.8% | $842.0M +11.3% | $756.7M +5.5% | $717.0M -43.2% | $1.3B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $883.7M +3178.3% | $27.0M +20.3% | $22.4M -38.8% | $36.6M -46.4% | $68.3M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | -$902.2M -21647.6% | $4.2M -76.8% | $18.0M -80.1% | $90.5M +1265.1% | $6.6M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $619.0M -65.7% | $1.8B +41.4% | $1.3B -50.1% | $2.6B -11.2% | $2.9B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 | $0 | $0 | $0 | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $924.6M | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 -100.0% | $15.1B | $0 | $0 -100.0% | $5.7M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $171.3M -99.0% | $16.4B +8.5% | $15.1B +6.1% | $14.2B -2.7% | $14.6B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $16.0B +205.8% | -$15.1B -231526.3% | $6.5M -78.0% | $29.6M +614.8% | $4.1M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $17.1B +3.9% | $16.4B +8.7% | $15.1B +6.0% | $14.3B -2.6% | $14.6B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $19.6B +7.7% | $18.2B +11.2% | $16.4B -2.6% | $16.8B -4.0% | $17.5B | $13.3B | $11.9B | $10.6B |
| Account Payables | $19.4M +45.1% | $13.4M -11.8% | $15.2M +91.8% | $7.9M +40.7% | $5.6M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $380.0M -61.9% | $997.8M | $0 -100.0% | $997.5M | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $164.0M +139.0% | $68.6M +503.1% | $11.4M -8.3% | $12.4M | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $636.2M -49.2% | $1.3B +676.8% | $161.4M -86.2% | $1.2B +581.3% | $171.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $8.6B +29.6% | $6.6B +7.8% | $6.1B +0.3% | $6.1B -13.8% | $7.1B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $682.6M +5550.8% | $12.1M +1242.2% | $900.0K -64.0% | $2.5M | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $9.3B +39.9% | $6.6B +8.0% | $6.1B +0.2% | $6.1B -13.7% | $7.1B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $9.9B +25.7% | $7.9B +25.1% | $6.3B -13.6% | $7.3B +0.3% | $7.3B | $14.7B | $3.7B | $9.6B |
| Common Stock | $106.0K -1.9% | $108.0K +0.0% | $108.0K +0.9% | $107.0K +0.9% | $106.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $2.4B -17.2% | $2.8B +13.0% | $2.5B +28.1% | $2.0B -12.9% | $2.3B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 -100.0% | $16.5M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $3.2B -4.6% | $3.4B -4.6% | $3.6B -8.7% | $3.9B -12.9% | $4.5B | $1.4B | $337.8M | $931.4M |
| Total Equity | $9.7B -6.1% | $10.3B +2.6% | $10.1B +5.9% | $9.5B -7.1% | $10.2B | $9.1B | $7.7B | $3.3B |
| Total Debt | $9.0B +17.6% | $7.6B +24.1% | $6.1B -13.8% | $7.1B +0.3% | $7.1B | $724.2M | $410.6M | $399.4M |
| Net Debt | $8.3B +24.7% | $6.7B +18.1% | $5.7B +4.7% | $5.4B -2.7% | $5.6B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
United Therapeutics Corporation
NASDAQ:UTHR
$23.00B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.79B
Incyte Corporation
NASDAQ:INCY
$21.78B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.37B
Tenet Healthcare Corporation
NYSE:THC
$15.26B
Exelixis, Inc.
NASDAQ:EXEL
$13.39B
Smith & Nephew plc
NYSE:SNN
$12.97B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.59B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does RPRX have?
Royalty Pharma plc (RPRX) reported $618.70M in cash and equivalents in fiscal 2025.
How much debt does RPRX carry?
Royalty Pharma plc (RPRX) reported $8.95B of total debt, with net debt of $8.33B.
Explore More
Continue the stock analysis
Jump to another research area for this company.